---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-007340"
form_type: "8-K"
ticker: "XBIO"
cik: "0001534525"
company_name: "Xenetic Biosciences, Inc."
filed_at: "2026-09-23T21:20:22+00:00"
generated_at: "2026-09-23T21:22:08.269846+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "medium"
source: SEC EDGAR
---

# Xenetic-Santersus share exchange values combined company at $141M; XBIO holders ~15%

## Summary
- Deal values Xenetic at ~$21M (15% pro forma) and Santersus at ~$120M (85%); 2,546,699 XBIO shares outstanding.
- Expected to close Q4 2026; combined company to trade on Nasdaq under ticker SNTS.
- NucleoCapture holds two FDA Breakthrough Device Designations; 80+ compassionate-use cases showed positive outcomes with no adverse events.
- Lead sepsis program (~$5.6B market) targets potential EU launch in Q2 2028; CAR T lymphoma efficacy data expected Q2 2027.
- Santersus options assumed by Xenetic; $0 net cash assumed, subject to adjustment per Share Exchange Agreement.

## SEC filing metadata
- accession: 0001683168-26-007340
- form_type: 8-K
- ticker: XBIO
- cik: 0001534525
- company_name: Xenetic Biosciences, Inc.
- filed_at: 2026-09-23T21:20:22+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534525/000168316826007340/0001683168-26-007340-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534525/000168316826007340/xenetic_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-007340
- JSON: https://secwatch.observer/filing/0001683168-26-007340.json
- Plain text: https://secwatch.observer/filing/0001683168-26-007340.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.